Context
Cellenkos develops allogeneic regulatory T-cell therapies grown from umbilical cord blood, designed to restore immune tolerance and calm inflammation in serious conditions with few treatment options. Its pipeline spans graft-versus-host disease, bone-marrow failure, and other rare immune-mediated disorders, and the products are intended to be made in batches, frozen, and shipped to treatment centers as inventory rather than made one patient at a time. The company runs its own cGMP manufacturing in Houston, which has supplied its early clinical material.
At the time of the engagement the company was preparing for the shift from clinical-scale supply to commercial supply: registrational work ahead, accelerated regulatory designations in play, a second and larger manufacturing site planned, and a small team that would have to grow into commercial, regulatory, quality, and finance functions it did not yet carry.
Challenge
Cellenkos is a clinical-stage biotechnology company developing allogeneic regulatory T-cell therapies from umbilical cord blood for severe autoimmune and inflammatory diseases with limited treatment options. With several therapies advancing through clinical development, the company wanted revenue projections tied to trial timelines and manufacturing capacity, a clearer view of where cost risk concentrates, and an organizational plan for growing the team toward commercialization. The revenue models had grown up indication by indication, so the open questions were how to make the path from patient population to treated patients consistent and easy to follow across the pipeline, how to reflect the operational limits on early supply rather than assume an instant ramp, and how much structure and delegation the leadership team should add before the next stage of growth.
How the team worked
The team worked from the company's existing Excel models rather than starting over, cleaning up the structure so the path from incidence and prevalence through eligibility, diagnosis, access, and treatment was easy to follow for each indication. Relapse, prevalent patients waiting for a therapy, and prophylactic use were made explicit instead of sitting inside one lump assumption, and payer and price effects were separated so the drivers of gross revenue and gross profit were visible on the face of the model.
Each indication then got a structure that matched how the disease actually behaves. One model was built as an incidence funnel with a relapse path back into later lines of therapy, another was anchored to the transplant population it would be used in, a third combined a one-time prevalent pool with a recurring incidence flow split across lines of therapy, and a fourth carried two paths at once so treatment use and preventive use around transplant could be read separately rather than double counted.
Commercialization research grounded the ramp in operational milestones: how quickly treatment centers could be certified for a thaw-and-infuse product that uses existing infusion workflows, how the frozen chain from plant to hospital affects the share of shipped doses actually administered, and how the tech transfer to a larger site would cap early volume. Regulatory work covered the accelerated designations the company was pursuing, the review timelines attached to them, and the enrollment risk of relying on a narrow set of trial sites.
On the budgeting and organizational side, the team drew on published work on rare-disease trials and on the structures of comparable public biotech companies, then translated the findings into a contingency-reserve benchmark that scales with clinical phase, a fixed-cost threshold policy, financial tool recommendations staged to the company's size, and an eight-week plan to build dashboards and pilot a monthly operations review before locking the cadence in.
Workstreams
- Reorganized and extended the company's revenue models for four pipeline therapies, building consistent patient funnels from epidemiology to treated patients and layering on payer mix and pricing assumptions.
- Tied the revenue ramp to real-world constraints, including treatment-center onboarding, cold-chain logistics, and the timeline for bringing a second manufacturing site online.
- Mapped clinical trial phases, accelerated FDA pathways, and regulatory risks, and compared international trial-site options against a US-first approach.
- Reviewed the major cost drivers behind clinical programs and general operations, and recommended recruitment and retention strategies, go and no-go checkpoints, fixed-cost controls, and a milestone-linked contingency reserve.
- Evaluated financial tools for the next stage of growth, including accounting platforms, ERP systems, and a fractional CFO model.
- Built a two-year organizational roadmap with proposed leadership hires, first-year and second-year org charts, a tiered decision framework, a RACI matrix, and a monthly reporting cycle.
What the team found
- Making the patient funnel explicit for each indication showed how much of the early forecast comes from clearing a waiting pool rather than from new cases each year.
- Because these are relapsing conditions, patients recycle back into later lines of therapy, so volume keeps building even when incidence stays flat.
- The commercialization work showed that early revenue is limited less by demand than by supply: center readiness, frozen-chain handling, and manufacturing throughput all cap the ramp.
- Comparing the accelerated regulatory routes made clear that the broader designations are easier to obtain while the narrower ones carry the stronger review benefits.
- Trial-site work showed enrollment pace, not trial design, as the main lever on timeline, and that adding sites earlier compounds through every later milestone.
- The cost review showed overhead growing on contractual, non-discretionary lines that do not flex with revenue timing, which is what makes a delayed quarter expensive.
What the client received
- Updated revenue projection models for four pipeline therapies with commercialization and capacity assumptions
- Commercialization analysis covering center certification, cold-chain handling, and manufacturing scale-up
- Clinical trial, regulatory pathway, and trial-site risk analysis with international site options weighed against a US-first route
- Cost driver review with recruitment, retention, and trial design recommendations
- Financial planning and budgeting recommendations with contingency reserve benchmarks and fixed-cost controls
- Financial tools evaluation covering accounting platforms, ERP options, and a fractional finance leadership model
- Two-year organizational plan with first-year and second-year org charts, hiring sequence, decision framework, and RACI matrix
- Monthly reporting cycle with department dashboards and an eight-week implementation timeline
- Final written deliverable and presentation deck
Outcome
Cellenkos now has an integrated view of how clinical progress, regulatory strategy, capital allocation, and organizational design interact. The revenue models are transparent and capacity-constrained, so leadership can see which assumptions move the forecast and test them one at a time. The budgeting work shows where cash risk concentrates and which controls hold it in place, and the two-year plan gives the leadership team a staged path for hiring, delegation, and reporting as the company scales toward commercial supply.
Recommendations
- Treat patient recruitment as the first cost lever: pair plain-language outreach through disease communities with registry and advocacy partnerships and clinician education so eligible patients are identified earlier.
- Improve retention with a hybrid trial design that keeps infusions at certified centers while moving routine assessments closer to where patients live, supported by individualized participant support.
- Set go and no-go checkpoints tied to interim readouts before trials begin, so the team can continue, pivot, or stop on defined signals rather than on sunk cost.
- Cap fixed-cost growth with quarterly thresholds and executive review on any line that runs past plan, lock multi-year terms on the fastest-growing service categories, and tie hiring to regulatory and manufacturing milestones.
- Size the contingency reserve to clinical phase and operating runway rather than holding a flat figure, and step it up as manufacturing scale-up and regulatory engagement widen the range of outcomes.
- Stage the finance function: keep tooling simple now, add part-time senior financial leadership to set controls and reporting, and move to a project-level ERP as trial and manufacturing accounting grows.
Next steps
- The client was handed rebuilt revenue models with the assumptions labeled and separated, so the team can update trial timelines, payer mix, or capacity and see the effect immediately.
- The client was handed a two-year organizational roadmap staged into foundation, integration, and scale phases, with a hiring sequence and the decision and RACI frameworks that go with it.
- The client was handed an eight-week implementation plan for the reporting cycle: map reporting lines, draft department dashboards, pilot one cycle, then finalize templates and train department heads.
- The client was handed a trial-site and regulatory risk view with international options weighed against a US-first route, to carry into decisions about where to activate next.